Clinical Trials Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Mar 21, 2021; 27(11): 1101-1116
Published online Mar 21, 2021. doi: 10.3748/wjg.v27.i11.1101
Table 3 Cox regression analysis of risk factors for hepatocellular carcinoma in patients with chronic hepatitis B who were calibrated with REACH-B
VariableRate ratio (95%CI)


Single factor
Multiple factors
Sex
Female1.0 (referent)1.0 (referent)
Male2.859 (1.835-6.112)a3.076 (1.975-8.437)a
Age (yr)
≤ 401.0 (referent)
> 402.677 (1.089-6.579)a
HBeAg
-1.0 (referent)
+0.614 (0.288-1.310)
DNA level, IU/L (log)
≤ 3 (1 × 103 IU/L)1.0 (referent)
3-6.30 (2 × 106 IU/L)1.130 (0.543-1.602)
> 6.302.604 (0.749-3.854)
ALT level, U/L
≤ 501.0 (referent)
50-2001.140 (0.728-6.676)
200-4003.310 (0.173-11.112)
> 4004.036 (1.678-7.234)a
AST level, U/L
≤ 401.0 (referent)
40-2000.592 (0.184-1.904)
200-4001.565 (0.124-2.581)
> 4008.059 (0.689-11.968)
TB level, U/L
≤ 231.0 (referent)
23-460.525 (0.211-1.308)
46-1151.349 (0.078-1.572)
> 1151.605 (0.125-2.936)
Treatment
Anti-inflammatory1.0 (referent)
Antiviral0.701 (0.207-1.313)
Antiviral after anti-inflammatory treatment0.874 (0.283-1.467)
Diabetes
No1.0 (referent)
Yes2.469 (1.079-5.649)a
Hypertension
No1.0 (referent)
Yes1.932 (0.650-5.748)
Family history of liver cancer
No1.0 (referent)1.0 (referent)
Yes30.924 (12.709-75.561)a23.463 (9.372-47.564)a